Navigation Links
Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
Date:6/25/2010

encouraged by the preclinical results with anti-GITR immunotherapy. This approach appears to induce unique mechanisms for augmenting antitumor immune responses and holds promise for treating malignancies in man," said Louis Vaickus, MD, Chief Medical Officer at Tolerx. "In a murine model of established colon cancer, the results, especially the complete remissions, were striking and these findings represent preclinical proof of concept for TRX518."

About TRX518

TRX518 is a targeted T-cell immunomodulator that binds to the glucocorticoid-induced tumor necrosis factor receptor (GITR) found on multiple types of T cells and other immune cells. Activated GITR plays a role in directing the antitumor immune response via activating tumor-antigen-specific T effector cells, as well as abrogating the suppression induced by inappropriately activated T regulatory cells. In preclinical studies, TRX518 achieved its targeted effect without compromising normal immune function and preclinical models suggest TRX518 may have a reduced risk of causing the serious inflammatory side effects that can result from cytokine release.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three preclinical candidates, TRX518, TRX585, and TRX385, which enhance immune responses and as such are being evaluated
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
2. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
5. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
8. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
9. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
10. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
11. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "Micro Market Monitor: ... to their offering. ... treatment is progressing steadily, which has resulted in ... devices market. The main purpose of these dermatology ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
... 22, 2011 The U.S. Food and Drug Administration ... Ann Arbor, Mich., and two of its officers, Mark ... Lincoln, vice president of Quality Assurance and Operations, have ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The ...
Cached Medicine Technology:Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
(Date:12/21/2014)... 21, 2014 CannabisClassifieds.com celebrates marijuana’s new legal ... only one of its kind, the site has provided its ... for 14 years running. It uniquely combines the benefits ... cannabis readily available to the masses. Assuring the potent ... golden ring of public approval. , Shane Chattin, ...
(Date:12/20/2014)... (PRWEB) December 21, 2014 BambooIndustry.com is ... flooring collections . The business has recently shown its ... offer on all its bamboo flooring models. , BambooIndustry.com’s ... North America, Asia and more. According to the CEO ... been developed very fast in the past few years, ...
(Date:12/20/2014)... 20, 2014 Weddingshe.com has recently announced ... a site-wide promotion of special occasion dresses for the ... supplier of special occasion dresses for global women. Now, ... big discounts, up to 80% off. Among the new ... Short Sweet 16 Dress) is very popular. What’s more, ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4
... , Dec. 24th Vote Looming, AARP Calls on Senators to ... of Idaho,s Health Care Woes , BOISE, Idaho, Dec. 23 ... families this holiday season, rising health care costs are an issue ... woes grow increasingly worse, AARP is calling on Senators Mike Crapo ...
... in study lost bone mass within two years , WEDNESDAY, ... who received the "birth control shot" -- also known as ... percent of their bone mineral density in the hip and ... who had never given birth and who didn,t consume much ...
... rolls around and you,re deciding whether to have another glass ... of the future. A pair of Kansas State University ... long term are more likely to make positive decisions about ... eat, or their decision to wear sunscreen. "If you ...
... , , LOUISVILLE, Ky., Dec. 23 ... companies today called on Congress to drop language that would ... food and beverage products prior to the point of sale, ... The requirement is included in both the House and ...
... , , , NEW YORK, Dec. ... by the Center for Disease Control and Prevention (CDC) and ... that approximately 673,000 children aged 3-21 have been diagnosed with ... that children with autism need increased access to evidence-based interventions, ...
... mushroom commonly used in Chinese medicine, could be made more ... works. The research is funded by the Biotechnology and Biological ... of Nottingham. In research to be published in the ... of The University of Nottingham and her team have investigated ...
Cached Medicine News:Health News:AARP Urges Idaho Senators Not to be the Grinches That Stole Health Care Reform 2Health News:Contraceptive Depo-Provera May Weaken Bones 2Health News:K-State psychologists show that future-minded people make better decisions for their health 2Health News:K-State psychologists show that future-minded people make better decisions for their health 3Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 2Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 3Health News:Autism Treatment Crisis: Insufficient Number of Providers to Meet Alarming Increase in Need 2Health News:Autism Treatment Crisis: Insufficient Number of Providers to Meet Alarming Increase in Need 3Health News:New insights into mushroom-derived drug promising for cancer treatment 2
Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
... innovative E.coli 0157 latex ... definitive identification of E.coli ... of a proprietary antibody ... of cross-reactions with Escherichia ...
Inquire...
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
Medicine Products: